Navigation Links
Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
Date:3/7/2011

CLEVELAND, March 7, 2011 /PRNewswire/ -- HGI Global Holdings, Inc., a leading provider of specialty medical products to chronic disease patients, today announced the appointment of Michael B. Petras, Jr. as Chief Executive Officer, effective March 21.

Mr. Petras, 43, joins HGI from GE Lighting, the Cleveland-based $3 billion unit of General Electric Company (NYSE: GE) where he served as President and Chief Executive Officer.  Michael has held general management positions within General Electric since 1995. Since 2005, he has been responsible for multi-billion dollar businesses, managing supply chain, marketing, finance, manufacturing, and engineering and administration functions.  

The CEO role has been vacant since October 2010, when HGI was acquired by Clayton, Dubilier & Rice, LLC (CD&R) and GS Capital Partners. Today's announcement follows the recent promotion of Kurt Packer to the position of President and Chief Operating Officer.

"Michael is a proven business builder with a passion for growing businesses and leading large, complex enterprises to new levels of financial and operating performance excellence," said Paul S. Pressler, Chairman of HGI and an Operating Partner at CD&R. "He is well versed in distribution businesses and will bring to the organization deep sales, marketing and brand management experience."

Mr. Petras said, "HGI is a very dynamic company operating in a large and growing market with a long history of improving the quality of patient care and lowering healthcare costs for patients and managed care organizations.  I look forward to working with the talented HGI team to build on their impressive accomplishments in serving its valued customer network and ultimately those people who depend on the specialty medical products the company distributes."

Prior to leading GE Lighting, Mr. Petras was Presi
'/>"/>

SOURCE HGI Global Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 China Biologic Products, Inc. (Nasdaq: ... integrated plasma-based biopharmaceutical company in China ... from a public announcement issued by Shanghai RAAS Blood ... on Shenzhen Stock Exchange, that on May 21, 2013, ... Chan"), one of the shareholders of the Company, and ...
(Date:5/24/2013)... The potential of the pulmonary ... therapeutic agents has been receiving undeniable attention with the ... promise. The crucial formulation considerations for orally inhaled products ... major role in the efficiency of pulmonary delivery, and ... new formulation techniques and devices in recent years. ...
(Date:5/23/2013)... SAN DIEGO y PARÍS, 24 de ... VOLC ), un destacado desarrollador y fabricante ... para mejorar la diagnosis y tratamiento de la ... resultados preliminares del ensayo ADVISE ( Ad enosine ... tenosis E valuation) II durante la sesión ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
(Date:5/25/2013)... Texas (PRWEB) May 25, 2013 ... stressful than finals week. Increasingly, they are turning ... stay awake and study. For more on this, ... a drug treatment facility, warns that students who ... finals” are at risk for developing a physical ...
(Date:5/25/2013)... Ayurveda is the traditional medicine ... wisdom of life". While a medical science, its scope enters ... consciousness. Its fundamental philosophy is that disease is the end ... believes that in order to re-establish optimal health, we must ... adopt a life style which brings us back into harmony. ...
(Date:5/25/2013)... Flagstaff, Arizona (PRWEB) May 25, 2013 The ... Rehabilitation Center, their parents, and the B2B staff all came ... While everyone enjoyed an array of Indian Cuisine, the residents ... the company, for helping them on their road to recovery, ... started the Drug and Alcohol center in 2010 after realizing ...
(Date:5/25/2013)... http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html , Resource4thePeople is ... of a jury's award of $6.5 million in damages ... the country over allegations that the diabetes drug Actos ... The judge in the case ruled that the man's ... was caused by the medication.** , Bloomberg News in ...
(Date:5/25/2013)... 25, 2013 AdvantaClean of Pikes Peak ... services for a healthy home and business in Colorado ... damage , mold inspections, mold testing, mold removal ... and coil cleaning. , With over 120 offices nationwide, ... industry offering a full suite of services for commercial, ...
Breaking Medicine News(10 mins):Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 2Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 3Health News:Grand Opening! AdvantaClean of Pikes Peak is Proud to Announce Water Damage Restoration, Mold Removal and Air Duct Cleaning Services to the Colorado Springs Area 4
... Grants New Indication for Bothersome Vaginal Symptom Associated,With ... estrogens) Vaginal Cream 0.5 g has been approved ... a new indication and a new less,frequent twice-weekly ... (painful sexual intercourse) announced Wyeth,Pharmaceuticals, a division of ...
... from patients with lung cancer and examining them under ... utilized to better tailor the chemotherapy treatments to improve ... according to a study presented at the 2008 Chicago ... IASLC and the University of Chicago., Cancer researchers have ...
... tumors of African-American non-small cell lung cancer patients are ... of the epidermal growth factor receptor (EGFR) gene and ... a study presented at the 2008 Chicago Multidisciplinary Symposium ... the University of Chicago., These genetic factors have been ...
... are one milliard of a metre in size are ... materials. There are also significant amounts of nanoparticles in ... their health effects, because only a very small portion ... and safety risks. Nanoparticles have even been dubbed the ...
... http://www.HealthCentral.com ) the leading collection of condition-specific,consumer ... a,broad initiative to sell advertising for any ... partners on a,non-exclusive basis and not require ... party rankings., "We are changing the ...
... those shoppers who,wake up at 4am on Black Friday? Not ... is important not to disturb your circadian rhythm and to ... body,operates better on a good night,s sleep which is why ... the day after Thanksgiving.", SSA retailers nationwide have an ...
Cached Medicine News:Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 2Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 3Health News:FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia - Painful Sexual Intercourse 4Health News:Research demonstrates differing genetic makeup of lung cancer in African-American patients 2Health News:Nanoparticles trigger cell death? 2Health News:HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences 2Health News:Don't Disturb Your Circadian Rhythm This Black Friday 'Sleep In, Nap Later,' says Specialty Sleep Association 2
The K-ASSAY Fibrinogen Control is an assayed quality control material intended for use in monitoring the accuracy and precision of the quantitative determination of fibrinogen....
The K-ASSAY Anti-Streptolysin O Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifyi...
Eppendorf expands its line of benchtop microcentrifuges with the 5418. This easy-to-use microcentrifuge features a certified aerosol-tight rotor and a unique, contoured rotor bowl design to reduce no...
... Directigen EZ Flu A+B test is a ... qualitative detection of influenza A and B ... swabs of symptomatic patients. The Directigen EZ ... such that influenza A viral antigens can ...
Medicine Products: